Weihao Xu
Founder & Chief Executive Officer Kali Therapeutics
Seminars
Wednesday 9th September 2026
Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?
11:45 am
- Pharma’s reflections on recent in vivo CAR-T and TCE deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
Thursday 10th September 2026
What can be Improved Upon for Existing Drugs?
9:00 am
- Discussing approaches to differentiate assets targeting competitive targets
- With clinical data so far, what constitutes a good outcome in autoimmune disease and which approach gets you there?
- Protocol design to define initial target indications, strategizing how to rapidly generate early clinical, proof-of-concept data, and differentiating company assets within competitive landscapes
